Development Of A Multi-Modality System For Onco-Imaging
Gultekin Gulsen, Assistant Professor
Ctr For Functional Onco-imaginguniversity Of California Irvine
Grant 4R33CA120175-02 from National Cancer Institute, IRG: ZRG1
Abstract: Recently, the optical imaging field has been rapidly expanding in scope through the use of new exogenous molecular probes. We have already developed a multi-frequency & multi- spectral optical tomography animal imaging system and integrated to an MRI system. In this application, we will expand our hybrid system to measure dynamic information from exogenous probes. This system would measure the enhancement kinetics of the bi-functional MR/NIR or mono-functional NIR contrast agents in addition to the endogenous contrast due to hemoglobin contents and scattering properties. There are two main phases of the proposal. The first and the foremost phase is the technology development, which can be classified into two sub aims a) the development of a novel multi-modality dynamic imaging system and b) the development of polymer based bi-functional and mono-functional NIR agents. We believe that such a hybrid system will facilitate the development of new contrast agents for biomedical imaging and that the development of polymer based molecular agents will provide a potential new molecular platform for these new contrast agents. In the second phase of the proposal, we will try to utilize this novel hybrid system together with a small molecular MR and a medium size (~30-40 kDa) novel polymer based optical agent. We will compare the role of all kinetic parameters and intrinsic properties obtained by MR/Optical imaging system, individually or combined, in cancer diagnosis after completing all analysis steps. Thus, we will be able to test our hypothesis that "the parameters obtained by macromolecular optical agent together with total hemoglobin, oxygen saturation and tissue scattering parameters can achieve a higher specificity in differentiating between ENU induced malignant and benign tumors compared to MRI parameters measured by low molecular weight extracellular MRI agents". We believe our collaboration with GE Global Research Center for the development of the novel MR/NIR contrast agents will serve to close the gap between the academia and the industries further for biomedical imaging applications. If successful, the outcome of our effort will offer a sophisticated tool that could provide high sensitivity and high specificity in the detection and characterization of tumors. With appropriate modifications in design, the proposed MR/Optical technology has a great translational potential for future human clinical trials. This application is aimed at developing a hybrid MR/DOT system along with novel polymer based contrast agents. If successful, the outcome of our effort will offer a sophisticated tool that could provide high sensitivity and high specificity in the detection and characterization of tumors
Project start date: 2007-08-01
Project end date: 2011-07-31
Sponsored Links Lab Supply Mall http://www.labsupplymall.com
Grants awarded to Gultekin Gulsen
Development Of A Multi-Modality System For Onco-Imaging
Gultekin Gulsen, Assistant Professor
Ctr For Functional Onco-imaginguniversity Of California Irvine
Grant 4R33CA120175-02 from National Cancer Institute, IRG: ZRG1
Abstract: Recently, the optical imaging field has been rapidly expanding in scope through the use of new exogenous molecular probes. We have already developed a multi-frequency & multi- spectral optical tomography animal imaging system and integrated to an MRI system. In this application, we will expand our hybrid system to measure dynamic information from exogenous probes. This system would measure the enhancement kinetics of the bi-functional MR/NIR or mono-functional NIR contrast agents in addition to the endogenous contrast due to hemoglobin contents and scattering properties. There are two main phases of the proposal. The first and the foremost phase is the technology development, which can be classified into two sub aims a) the development of a novel multi-modality dynamic imaging system and b) the development of polymer based bi-functional and mono-functional NIR agents. We believe that such a hybrid system will facilitate the development of new contrast agents for biomedical imaging and that the development of polymer based molecular agents will provide a potential new molecular platform for these new contrast agents. In the second phase of the proposal, we will try to utilize this novel hybrid system together with a small molecular MR and a medium size (~30-40 kDa) novel polymer based optical agent. We will compare the role of all kinetic parameters and intrinsic properties obtained by MR/Optical imaging system, individually or combined, in cancer diagnosis after completing all analysis steps. Thus, we will be able to test our hypothesis that "the parameters obtained by macromolecular optical agent together with total hemoglobin, oxygen saturation and tissue scattering parameters can achieve a higher specificity in differentiating between ENU induced malignant and benign tumors compared to MRI parameters measured by low molecular weight extracellular MRI agents". We believe our collaboration with GE Global Research Center for the development of the novel MR/NIR contrast agents will serve to close the gap between the academia and the industries further for biomedical imaging applications. If successful, the outcome of our effort will offer a sophisticated tool that could provide high sensitivity and high specificity in the detection and characterization of tumors. With appropriate modifications in design, the proposed MR/Optical technology has a great translational potential for future human clinical trials. This application is aimed at developing a hybrid MR/DOT system along with novel polymer based contrast agents. If successful, the outcome of our effort will offer a sophisticated tool that could provide high sensitivity and high specificity in the detection and characterization of tumors
Project start date: 2007-08-01
Project end date: 2011-07-31
1R21CA120175-01A2 (2007): $224585
Polarization Sensitive OCT For Detection Of Melanoma
Gultekin Gulsen, Assistant Researcher
University Of California Irvine Irvine, Ca 926977600
Grant 5R21CA097304-02 from National Cancer Institute, IRG: RNM
Abstract: Optical Coherence Tomography (OCT) is a recently developed imaging technology, which permits in-situ, real-time, non-invasive, non-contact, cross-sectional imaging of micron-scale structures in biological tissues and as such seems to be a suitable modality for the study of skin cancer. The development of polarization sensitive optical coherence tomography (PS-OCT) permits the acquisition additional information on the polarization properties of tissue carried by the reflected light. Malignant melanoma, a form of skin cancer, is increasing in incidence at the most rapid rate of all cancers. Yet detection of melanoma visually, even by experts in melanoma, has only 60-80% sensitivity. Thus, new methods of analyzing suspicious skin lesions in vivo are urgently needed. In this proposed study, we will construct a PS-OCT system to distinguish between normal, benign and malignant tissues. The PS-OCT system will control the polarization state of the light incident upon the sample. By measuring the reflectivity of light returning in particular polarization states we will obtain the Mueller matrix that provides complete representation of the polarization properties of the sample. During the first year of this project, we will complete construction and refinement of a high speed PS-OCT system by using a rapid scan optical delay line. In the second year, a transgenic mouse model will be used in conjunction with PS-OCT to study multistage melanoma carcinogenesis and differentiation of benign and 1 malignant lesions. This transgenic mouse model uses tyrosinase promoter to target expression of the mutated human T24 Ha-ras oncogene, as previously developed by Dr. Powell who will serve as a consultant in the second year. The overall goals of developing a system capable of determining benign from malignant pigmented lesions will be achieved through the following specific aims (1) develop PS-OCT instrumentation, (2) compare PS-OCT and histology to differentiate benign from malignant lesions. Successful completion of this pilot project will further the development of a practical and inexpensive device that can be used to differentiate benign from malignant lesions of the skin. Thus this research will have the potential to improve patient care and reduce the human and economical cost of melanoma.
Keywords: biomedical equipment development, diagnosis design /evaluation, melanoma, neoplasm /cancer diagnosis, noninvasive diagnosis, optical coherence tomography, carcinogenesis, cell differentiation, contrast media, disease /disorder model, gene expression, genetic promoter element, monophenol monooxygenase, mutant, neoplastic cell, neoplastic growth, oncogene, optical polarization, pigment, preneoplastic state, bioimaging /biomedical imaging, histology, laboratory mouse, transgenic animal
Project start date: 2002-07-01
Project end date: 2005-06-30
5R21CA097304-02 (2003): $189375
1R21CA097304-01 (2002): $176500
Related Publications
A simulation study of the variability of indocyanine green kinetics and using structural a priori information in dynamic contrast enhanced diffuse optical tomography (DCE-DOT). Phys Med Biol. 2008 Jun 21; 53( 12): 3189-200. Epub 2008 May 27. PMID: 18506072 Effects of the time dependence of a bioluminescent source on the tomographic reconstruction. Appl Opt. 2008 Feb 20; 47( 6): 799-806. PMID: 18288229 Diffuse optical tomographic reconstruction using multifrequency data. J Biomed Opt. 2006 Sep-Oct; 11( 5): 054008. PMID: 17092157 Combined diffuse optical tomography (DOT) and MRI system for cancer imaging in small animals. Technol Cancer Res Treat. 2006 Aug; 5( 4): 351-63. PMID: 16866566 Design and implementation of a multifrequency near-infrared diffuse optical tomography system. J Biomed Opt. 2006 Jan-Feb; 11( 1): 014020. PMID: 16526897 Coregistration of diffuse optical spectroscopy and magnetic resonance imaging in a rat tumor model. Appl Opt. 2003 Jun 1; 42( 16): 2951-9. PMID: 12790444 In vivo quantification of optical contrast agent dynamics in rat tumors by use of diffuse optical spectroscopy with magnetic resonance imaging coregistration. Appl Opt. 2003 Jun 1; 42( 16): 2940-50. PMID: 12790443 Congruent MRI and near-infrared spectroscopy for functional and structural imaging of tumors. Technol Cancer Res Treat. 2002 Dec; 1( 6): 497-505. PMID: 12625777 A double end-cap birdcage RF coil for small animal whole body imaging. J Magn Reson. 2002 Jun; 156( 2): 309-12. PMID: 12165267 Automatic tuned MRI RF coil for multinuclear imaging of small animals at 3T. J Magn Reson. 2002 Mar; 155( 1): 39-44. PMID: 11945031